Details of the Drug

General Information of Drug (ID: DMWOF1E)

Drug Name
SKY59
Synonyms Crovalimab; RO7112689
Indication
Disease Entry ICD 11 Status REF
Haemolytic uraemic syndrome 3A21.2 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
UNII
H9KH1GP3UU
DrugBank ID
DB16128
TTD ID
D1O9XQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Haemolytic uraemic syndrome
ICD Disease Classification 3A21.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04861259) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a). U.S. National Institutes of Health.
2 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.